0001062993-24-010179.txt : 20240514 0001062993-24-010179.hdr.sgml : 20240514 20240514163224 ACCESSION NUMBER: 0001062993-24-010179 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240510 FILED AS OF DATE: 20240514 DATE AS OF CHANGE: 20240514 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Frieberg Jacob B. CENTRAL INDEX KEY: 0001748346 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38624 FILM NUMBER: 24944985 MAIL ADDRESS: STREET 1: 1895 MOUNT HOPE AVENUE CITY: ROCHESTER STATE: NY ZIP: 14620 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VACCINEX, INC. CENTRAL INDEX KEY: 0001205922 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 161603202 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1895 MOUNT HOPE AVE CITY: ROCHESTER STATE: NY ZIP: 14620 BUSINESS PHONE: 585-271-2700 MAIL ADDRESS: STREET 1: 1895 MOUNT HOPE AVE CITY: ROCHESTER STATE: NY ZIP: 14620 FORMER COMPANY: FORMER CONFORMED NAME: VACCINEX INC DATE OF NAME CHANGE: 20021114 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0508 4 2024-05-10 0001205922 VACCINEX, INC. VCNX 0001748346 Frieberg Jacob B. C/O VACCINEX, INC. 1895 MOUNT HOPE AVENUE ROCHESTER NY 14620 1 0 0 0 0 Common Stock 303 D Common Stock 451 I By Benbow Estates, Ltd. Common Stock 920 I By Gee Eff Services Limited Stock Option (Right to Buy) 2856.0 2027-09-15 Common Stock 30 30 D Stock Option (Right to Buy) 1104.6 2029-03-30 Common Stock 11 11 D Stock Option (Right to Buy) 1633.8 Common Stock 36 36 D Stock Option (Right to Buy) 1159.2 2029-06-29 Common Stock 11 11 D Stock Option (Right to Buy) 1505.7 2029-09-27 Common Stock 8 8 D Stock Option (Right to Buy) 1018.5 2029-12-28 Common Stock 13 13 D Stock Option (Right to Buy) 840.0 2030-03-29 Common Stock 15 15 D Stock Option (Right to Buy) 829.5 Common Stock 74 74 D Stock Option (Right to Buy) 758.1 2030-06-28 Common Stock 17 17 D Stock Option (Right to Buy) 373.8 2030-09-28 Common Stock 36 36 D Stock Option (Right to Buy) 434.7 2030-12-29 Common Stock 31 31 D Stock Option (Right to Buy) 625.8 2031-03-31 Common Stock 21 21 D Stock Option (Right to Buy) 451.5 Common Stock 136 136 D Stock Option (Right to Buy) 588.0 2031-06-28 Common Stock 22 22 D Stock Option (Right to Buy) 453.6 2031-09-28 Common Stock 29 29 D Stock Option (Right to Buy) 218.4 2031-12-29 Common Stock 61 61 D Stock Option (Right to Buy) 277.2 2032-03-28 Common Stock 47 47 D Stock Option (Right to Buy) 235.2 Common Stock 253 253 D Stock Option (Right to Buy) 226.8 2032-06-27 Common Stock 57 57 D Stock Option (Right to Buy) 104.02 2032-09-27 Common Stock 125 125 D Stock Option (Right to Buy) 135.52 2032-12-28 Common Stock 94 94 D Stock Option (Right to Buy) 83.86 2033-03-28 Common Stock 152 152 D Stock Option (Right to Buy) 86.1 Common Stock 684 684 D Stock Option (Right to Buy) 74.76 2033-06-27 Common Stock 172 172 D Stock Option (Right to Buy) 5.75 2024-05-10 4 A 0 2211 3.96 A 2024-05-10 2034-05-10 Common Stock 2211 2211 D Stock Option (Right to Buy) 5.75 2024-05-10 4 A 0 10108 0 A 2025-05-10 Common Stock 10108 10108 D Mr. Frieberg's spouse is the owner of Benbow Estates, Ltd. and Mr. Frieberg is an officer of Benbow Estates, Ltd. Mr. Frieberg disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. Mr. Frieberg is the sole owner and President of Gee Eff Services Limited. Exercisable in full as of the date of this report. This option expires on May 14, 2029 or five years following retirement or cessation of services, whichever occurs first. This option expires on May 12, 2030 or five years following retirement or cessation of services, whichever occurs first. This option expires on May 9, 2031 or five years following retirement or cessation of services, whichever occurs first. This option expires on May 9, 2032 or five years following retirement or cessation of services, whichever occurs first. This option expires on May 8, 2033 or five years following retirement or cessation of services, whichever occurs first. Pursuant to the Issuer's Director Compensation Plan, in a transaction exempt under Rule 16b-3, the reporting person elected to receive these options in lieu of $8,750 for retainer and meeting fees during the first quarter of 2024. The number of options was calculated in accordance with the Black-Scholes valuation model and all such options are immediately exercisable. This option was granted pursuant to the Company's 2018 Omnibus Incentive Plan in a transaction exempt under Rule 16b-3 and expires on May 10, 2034 or five years following retirement or cessation of services, whichever occurs first. On February 19, 2024, Vaccinex, Inc. effected a 1-for-14 reverse stock split (the "Reverse Stock Split"). The number of stock options and underlying shares of common stock in this Form 4 reflect the Reverse Stock Split. /s/ Maurice Zauderer, Attorney-in-Fact for Jacob Frieberg 2024-05-14